Kyuson Yun

Kyuson Yun

Associate Professor of Cancer Biology in Neurology
The Yun lab focuses on elucidating mechanisms that promote dysregulated immune activation in brain cancer and neurodegeneration, particularly in a sex-biased manner.
Program Affiliations
Research

My lab’s long-term goal is to elucidate mechanisms that mediate brain disease progression, focusing on brain tumors and neurodegenerative diseases. Our observations over the years and new knowledge in the field indicate that the immune system plays a critical role in modulating neurodegeneration, cancer progression, immune evasion, and therapy resistance.

Figure 1.

Yun Lab

In the last several years, my laboratory leveraged our expertise in mouse modeling, single cell genomics, spatial transcriptomics, and brain cancer biology to study the interface between brain cancer cells and their microenvironment to identify novel therapeutic targets. For example, from our large single cell RNA-seq and spatial transcriptomics data from human GBM, we discovered new foundational insights and identified new therapeutic targets, such as S100A4. With our collaborators, we developed a novel bispecific S100A4-TfR antibody that crosses the BBB and reprograms the GBM TME to sensitize it to anti-PD1 immune checkpoint inhibitors.

In addition, we became interested in how the biological sex affects immune responses in the brain from our recent study demonstrating that an oncogene YAP1 has a sex-biased function in promoting immune evasion medulloblastoma. Building on this discovery, we are now working on other sex biased immune regulation in the brain, including sex-biased neuroinflammation in Alzheimer’s disease.

Biography

Dr. Yun began her independent research career at the Jackson Laboratory in Maine, where she built a research program focused on brain cancer stem cells (CSCs). She utilized her expertise in developmental and stem cell biology, genetics/genomics, and mouse modeling to elucidate fundamental properties of cancer stem cells at the molecular and cellular levels and to identify their unique vulnerabilities to target them for eradication.Her lab identified several novel regulators of brain cancer stem cells (such as S100A4 and YAP1) and mechanistic studies of those molecules led her to explore the link between cancer stem cells and immune modulation.

Since moving to Houston Methodist, her laboratory redirected its focus to neuroinflammation. For example, her lab performed extensive single cell RNA-seq analysis from human glioma patients to elucidate the cellular heterogeneity and cell: cell communication among cancer and immune cells, particularly myeloid cells, that promote immune evasion and tumor progression. Yun laboratory is currently translating these findings by developing therapeutic antibodies and small molecules against dual regulators of cancer stem cells and immune suppressive microenvironment. More recently, these studies have led to sex differences in immune response to cancer and neurodegeneration. Active projects in the lab include elucidating mechanisms that lead to sex-specific immune mechanisms that promote brain cancer and Alzheimer’s disease and myeloid differentiation/activation in the tumor microenvionment and neurodegenerative diseases.

Dr. Yun is the inaugural Houston Methodist Chair of Neurodegenetiave Disease Research. She is an American Cancer Society Research Scholoar and serves as a member of the Scientific Advisory Board of the American Brain Tumor Association, an editorial board member for Scientific Reports, and standing member of a NIH study section. She reviews for top journals in her field and grants applications for US and international government agencies (NIH, DoD, NSF, MRC (UK), Italian Ministry) as well as many foundations. Outside of the lab, she is a cofounder of EMPIRI and in her spare time, can be found walking around Rice University listening to various entrepreneurial and scientific podcasts.

Distinctions: 

  • Houston Methodist Chair in Neurodegenerative Disease Research (2025)
  • Board of Scientific Advisory Council, American Brain Tumor Association (2018-2026)
  • Presidential Award, Excellence in Peer Reviewed Publication, HMRI (2025, 2022)
  • Standing Member, NIH CNBT study section (2023-2027)
  • American Cancer Society Research Scholar (2009)
  • Keystone Symposium Travel Scholarship: Cell Cycle and Development (2004)
  • Tourette Syndrome Foundation Postdoctoral Fellowship (1998-2000)
  • The Ferguson Prize for Outstanding Undergraduate Teaching, California Institute of Technology (1995)

Selected Publications: 

  • Nourhan Abdelfattah, Sivaraman Natarajan, Han Nhat Tran, Thomas Wong, Maryam Faisal, Jose Maldonado, Rachael McMinimy, Hannah Borland, Shu-hsia Chen, Hong Zhao, Matthew Vasquez, Freddys F. Rodriguez, Carston R. Wagner, Fernando Camargo, James Olson, Joshy George, Kyuson Yun. Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma, (2026), Cancer Cell, Volume 44, Issue 4P760-776. E8April 13, 2026
  • Van K. Morris, Christine M. Parseghian, Lianchun Xiao, Nourhan Abdelfattah, Kanwal P. S. Raghav, Robert A. Wolff, Arvind Dasari, Ryan W. Huey, Benny Johnson, Bryan K. Kee, Michael S. Lee, Michael J. Overman, Jason A. Willis, Phat H. Le, Michelle Escano, C. Baig, Kelsey Pan, Alda L. Tam, Wai C. Foo, Vahid Bahrambeigi, Li Shen, Thomas D. Gallup, Cori Margain, Dave Gallup, Sharia Hernandez, Vittorio Branchi, Kimal I. Rajapakshe, Paola A. Guerrero, Jing Wang, Luisa M. Solis Soto, Anirban Maitra, Kyuson Yun*, Scott E. Kopetz*, Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable, BRAFV600E metastatic colorectal cancer (2025), Cancer Cell, Volume 43, Issue 11P2106-2118.E3 DOI: 10.1016/j.ccell.2025.08.002
  • Jia-Shiun Leu, Hui Deng, Han Nhat Tran, Xiong Wei, Nourhan Abdelfattah, Thomas Wong, Reece Kang, Chihiro Hashiomoto, Fransisca Leonard, Sinem Gunalp , José M Benítez Salazar, Jose A. Maldonado, Carlo D. Cristobal, Hyun Kyoung Lee, Zhiqiang An, Ningyan Zhang, Kyuson Yun, Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis, 2026, Cancer Letters, Vol 649, (available online April 8, 2026). https://doi.org/10.1016/j.canlet.2026.218491
  • Abdelfattah N, Kumar P, Wang W, Leu J, Flynn WW, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood S, Powell S, Haviland D, Lang F, Prabhu S, Huntoon K, Kim Y, Jiang W, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target, Nature Communications, 13, 767 (2022). https://doi.org/10.1038/s41467-022-28372-y 
Back to Top